Showing Results for
- Academic Journals (11)
Search Results
- 11
Academic Journals
- 11
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedFirst off, Happy New Year! Our January/February is a single issue, thus the reason for its arrival in your inbox in February. The Applied Clinical Trials team just got back from SCOPE, the Summit for Clinical Operations...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedIn 2021, a Tufts Center for the Study of Drug Development study showed that a typical Phase III clinical trial generates 3.56 million data points. (1) If we consider that number from another angle --that just 20% of...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedMural Health Technologies, Inc., a global provider of clinical trials technology, launched its new participant-facing technology platform, Mural Link, at the CNS Summit in November in Boston. Sam Whitaker, co-founder and...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedThe ability to reuse eSource--the highquality, structured data that clinicians have started to capture every day in hospitals' electronic health records (EHRs)--is, in my view, a sure-fire way to make clinical trials...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedDrawing insights from industry news and the findings of a survey of over 150 pharma and biotech leaders conducted by the PPD clinical research business of Thermo Fisher Scientific (view here: https://bit.ly/3HNXFD5), the...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedInnovation in feasibility tools and data platforms has opened doors to new possibilities for clinical trial design and management. However, amid an increasingly complex data and therapeutic landscape, understanding how...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedBy now, some of the dust is beginning to settle on the controversial refusal by the European Union to extend its Jan. 31 deadline for compliance with its new Clinical Trials Regulation, and attention among the clinical...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedA detailed report from key House Committees blasts FDA's role advising, assessing, and providing accelerated approval in 2021 for Biogen's controversial Alzheimer's disease treatment Aduhelm Jaducanumab). The critique...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedThe well-recognized potential of sensorbased digital health technologies (DHTs) as drug development tools has not led to their widespread adoption by drug developers as originally anticipated. (1) Part of the problem is...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedOur first issue of 2023 focuses on data management. Fresh off of attending SCOPE (Summit for Clinical Ops Executives) in Orlando, FL, our Applied Clinical Trials editorial team noticed that data management had a rather...
-
From:Applied Clinical Trials (Vol. 32, Issue 1-2) Peer-ReviewedClinical research is evolving rapidly, with the digitalization of trials creating a new modus operandi and a tsunami of new opportunities for critical thinkers with an eye for data quality. According to the job's...